Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Clin Endosc > Volume 51(3); 2018 > Article
Review Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer
Seiichiro Abe1orcid, Ichiro Oda1, Takeyoshi Minagawa2, Masau Sekiguchi1, Satoru Nonaka1, Haruhisa Suzuki1, Shigetaka Yoshinaga1, Amit Bhatt3, Yutaka Saito1
Clinical Endoscopy 2018;51(3):253-259.
DOI: https://doi.org/10.5946/ce.2017.104
Published online: September 18, 2017

1Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan

2Department of Gastroenterology, Tonan Hospital, Sapporo, Japan

3Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland, OH, USA

Correspondence: Seiichiro Abe Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo 104-0045, Japan Tel: +81-3-3542-2511, Fax: +81-3-3542-3815, E-mail: seabe@ncc.go.jp
• Received: June 29, 2017   • Accepted: July 27, 2017

Copyright © 2017 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 11,955 Views
  • 301 Download
  • 38 Web of Science
  • 44 Crossref
  • 40 Scopus
prev next
Full Article

Download PDF Download PDF

  • This review article summarizes knowledge about metachronous gastric cancer (MGC) occurring after curative endoscopic resection (ER) of early gastric cancer (EGC), treatment outcomes of patients who developed MGC, and efficacy of Helicobacter pylori eradication to prevent MGC. The incidence of MGC following curative ER increases over time and is higher than in patients undergoing gastrectomy. Increasing age and multifocal EGC are independent risk factors for developing MGC. An MGC following curative ER is usually a small (<20 mm) and differentiated intramucosal cancer. Most MGC lesions are found at an early stage on semiannual or annual surveillance endoscopy and are successfully treated by further ER, with excellent long-term outcomes. Eradication of H. pylori may reduce the risk of MGC following ER of EGC, but further prospective studies with long-term outcomes are required. Surveillance endoscopy following gastric ER should be continued indefinitely, due to the risk of MGC even after successful H. pylori eradication. Risk stratification and tailored endoscopic surveillance schedules need to be developed.
  • Keywords: Metachronous gastric cancer; Endoscopic resection; Endoscopic mucosal resection; Helicobacter pylori; Surveillance endoscopy
Approximately one million new gastric cancer cases occurred in 2012, making it the fifth most common malignancy and the third leading cause of cancer death worldwide [1]. Development of screening esophagogastroduodenoscopy (EGD) programs has led to the detection of gastric cancer at earlier stages, and approximately half of all gastric cancers in Japan are detected at a stage when they are confined to the mucosa or submucosa [2].
Increasing numbers of early gastric cancer (EGC) cases have been treated with endoscopic resection (ER), as curative resection was defined based on large retrospective cohort in surgery cases and the development of endoscopic submucosal dissection (ESD) has allowed for high en bloc and curative resection rates of EGC, regardless of size and location [3-6]. Several retrospective studies have shown excellent long-term outcomes in EGC patients undergoing curative gastric ESD [7-16]. In addition, ESD preserves stomach function and maintains quality of life in those patients who achieve curative ER [17].
A drawback of ER for EGC is the risk of developing metachronous gastric cancer (MGC) in the remaining native stomach. As the popularity of this technique increases, it is vitally important to characterize risk factors and long-term outcomes for those patients who develop MGC. This review article summarizes the definition, incidence, clinical characteristics, and outcomes of MGC.
Gastric cancer detected on surveillance EGD following curative ER may be a de novo lesion, a previously invisible preclinical lesion, or a missed lesion. Determining which of these possibilities is the case can be extremely difficult. General consensus, based on previous publications, is that gastric cancers detected within 1 year after ER should be regarded as a missed synchronous gastric cancer [18-21]. Thus, MGC is generally defined as a gastric cancer located distant from the original EGC over 1 year following index ESD.
Studies have reported an incidence of MGC following ER for EGC ranging from 2.7% to 15.6% (Table 1) [20,22-30]. In these studies, all MGCs were detected on surveillance EGD, and no study reported detection of EGC by barium contrast or computed tomography. ESD was preferred over endoscopic mucosal resection (EMR) in these series.
Kobayashi et al. reported that MGCs developed in 30 of 234 patients during a median follow-up of 5.0 years [28]. They also demonstrated that a Kaplan-Meier curve of cumulative incidence of MGC stopped increasing after 10 years of follow-up [28]. In contrast, Kato et al. and Min et al. reported that the cumulative incidence curve revealed a linear increase in much larger cohorts [24,29]. We also demonstrated that 5-year, 7-year, and 10-year cumulative incidence of MGC (adjusted for risk of death from other causes) on surveillance endoscopy was 9.5%, 13.1%, and 22.7%, respectively, with a median follow up of 82.2 months [30].
Following gastrectomy, the cumulative incidence of MGC is 0.9%–3.0% [31-34]. The incidence of MGC in patients undergoing ER is much higher. This difference is explained by the organ-sparing nature of ER, as while maintaining luminal continuity offers an improved quality of life, the remaining gastric mucosa continues to be at risk of MGC.
Although methods used to analyze risk factors for MGC vary among studies, older age, multiple initial EGCs and persistent Helicobacter pylori infection are considered to be common risk factors (Table 2) [25,28-30,35-37]. As older age is a greater potential risk factor for gastric cancer and multifocal lesions tend to develop in gastric mucosa with high risk field changes, these factors are unsurprising. Persistence of H. pylori infection as a risk factor is less straightforward. Persistence should be positively correlated with recurrence risk; however, Lim et al. reported that the absence of H. pylori infection is an independent risk factor for metachronous neoplasms, including dysplasia [38]. One possible explanation for this divergent finding is that long-term H. pylori infection may result in severe atrophic gastritis with intestinal metaplasia, such that H. pylori is no longer detectable. Long-term infection might have had more effect on metachronous tumorigenesis than newly developed H. pylori infections that can be easily detected [39].
According to recent publications, MGCs are commonly characterized as small, differentiated intramucosal cancers <20 mm in size [26-28]. MGCs often develop when the initial lesion is a differentiated EGC. This suggests that this type of cancer tends to develop in gastric mucosa during field cancerization [40,41].
Regular endoscopic surveillance detects MGC at an early stage, allowing for repeat curative ESD resection in the majority of cases, according to absolute or expanded indications based on the Japanese Gastric Cancer Treatment Guidelines [5,23-25,29,30]. Kato et al. reported that only 4 of 175 synchronous or metachronous cancers invaded the submucosa or deeper layers [24]. Our study showed that 215 of 238 patients with MGC underwent ER (mostly ESD), and the en bloc resection, R0 resection, and curative resection rates were 99.3%, 94.3%, and 88.8%, respectively [30].
In addition, excellent long-term outcomes have been shown by Kato et al. in his multicenter, retrospective cohort study, in which no patients died of gastric cancer during a mean follow-up period of 26.8 months [24]. Our study showed a 5-year disease-specific survival rate of 99.2% in patients undergoing curative gastric ESD; of the 238 patients who developed MGC, only 7 died of MGC during a median follow-up of 82.2 months. The patients who died from MGC were lost to follow-up, and did not undergo the surveillance endoscopy that may have detected their cancers at an earlier and more treatable stage. Five of the patients died from MGC more than 5 years after their index ESD.30 These studies support the clinical validity of an organ-preserving strategy with surveillance endoscopy and repeated ESD.
Treatment outcomes for gastric cancer are generally evaluated with 5-year overall and disease-specific survival. A limited 5-year follow-up may be reasonable for patients undergoing gastrectomy, as a majority of postoperative lymph node or distant recurrences occur within 5 years, and the risk of MGC development is much lower than in those treated with ER [42]. On the other hand, indefinite endoscopic surveillance is required to detect and remove MGCs in patients treated endoscopically.

H. PYLORI ERADICATION FOLLOWING ER

H. pylori infection is characterized by progression through the following stages: chronic active gastritis, atrophy, intestinal metaplasia, and dysplasia, followed by the development of gastric adenocarcinoma. H. pylori infection is considered one of the most important risk factors for gastric cancer [43-47]. In 1994, the International Agency for Research on Cancer, a subsidiary of the World Health Organization, categorized H. pylori as a group 1 carcinogen for gastric cancer [48]. Uemura et al. concluded that gastric cancer develops in persons infected with H. pylori, but not in uninfected persons [49]. Take et al. showed that H. pylori eradication has preventative effects on the occurrence of initial gastric cancer [50]. In addition, persistent H. pylori infection was considered to a risk factor for MGC after ER in a number of retrospective studies, as shown in Table 2 [36,37].
Thus, it would seem reasonable to assume that H. pylori eradication would have a potential prophylactic effect on MGC following ER [51]. However, two recent large, prospective randomized trials have shown contradictory results. Fukase et al. reported that the cumulative incidence of MGC was 6.5% during a 3-year follow-up, and patients receiving H. pylori eradication treatment showed significantly lower MGC rates than patients without eradication therapy (3.5% vs. 9.6%, p=0.003) [52]. On the other hand, Choi et al. concluded that the cumulative incidence of MGC was comparable in patients with and without H. pylori eradication treatment during a 3-year follow-up (2.3% vs. 3.9%, p=0.24) [53]. Other retrospective studies showed similarly controversial conclusions (Table 3) [35-37,54-58], but meta-analyses by Jung et al. and Yoon et al. concluded that H. pylori eradication could play a preventative role by reducing the occurrence of MGC in patients who have undergone ER [59,60].
Therefore, H. pylori eradication should be considered as preventative of MGC after ER. It should be noted that the definitions of MGC were not consistent among the studies and that some previous studies did not distinguish MGC from synchronous gastric cancer. In addition, the median follow-up periods were less than 5 years in a majority of previous publications and the timing of H. pylori eradication could affect the results. Further prospective studies in the ESD era with long follow-up periods might help clarify the preventative effect of H. pylori eradication for MGC occurrence.
MGCs following successful H. pylori eradication were mainly characterized as small, differentiated EGCs. Mori et al. showed that MGCs were 15 mm in median tumor size, and were commonly located at the middle or lower third of the stomach [61]. Of these, 97% of MGCs were differentiated EGCs and 90% of these were confined to the mucosa. Curative ESD resection was done for all MGCs according to the Japanese Gastric Cancer Treatment Guidelines, except for one differentiated T1b (submucosal invasion to 80 μm) cancer 4 mm in size with lymphatic involvement [61]. Regular endoscopic surveillance would probably play a significant role in early detection. MGCs following H. pylori eradication were sometimes covered by non-neoplastic epithelium.
This histological alteration made it more difficult to detect MGC and delineate its margin, even with magnified narrow-band imaging [62,63]. Yamamoto et al. reported that the average diameter of an MGC following successful eradication was smaller and the Ki-67 index was lower than in cases with persistent H. pylori infection [64].
Moribata et al. analyzed endoscopic mucosal background features associated with MGC in patients who underwent H. pylori eradication therapy and concluded the absence of intestinal metaplasia prior to ESD was a negative predictor of MGC after ESD, and the emergence of map-like redness after H. pylori eradication was a positive predictor for MGC after ESD [65]. Mori et al. and Shiotani et al. supported this conclusion and showed that widespread gastric mucosal atrophy and multiple gastric cancers before successful H. pylori eradication were risk factors for MGC occurrence following H. pylori eradication [54,61].
There are some established guidelines for surveillance interval in patients undergoing curative ER. The National Comprehensive Cancer Network guidelines state that even for Tis or T1 with N0 lesions achieving R0 with ER or surgery, all patients should be followed up systematically, and follow-up should include a complete history and physical examination every 3 to 6 months for 1 to 2 years, every 6 to 12 months for 3 to 5 years, and annually thereafter all patients [66]. The Japanese gastric cancer treatment guidelines recommend annual or biannual endoscopy after curative ESD for patients with EGC who meet expanded indications criteria [5].
Given that most of the MGCs were found in early stages and were successfully treated with ER in many previous reports, annual or biannual endoscopic surveillance may be reasonable. As the individual risk of MGC can vary greatly among patients, risk stratification and tailored follow-up schedules should be considered, similar to surveillance colonoscopy after endoscopic polyp removal [67]. In addition, we are performing a prospective study to evaluate epigenetic cancer risk prediction of MGC after H. pylori eradication. We hope that these results will provide more detailed data on the stratification of risk factors for MGC following H. pylori eradication [68]. Further prospective studies are warranted to determine appropriate surveillance intervals. Regarding the surveillance period, as the cumulative incidence of MGC linearly increased and some patients died of MGC more than 5 years after treatment, endoscopic surveillance should be performed indefinitely [30]. In addition, Mori et al. reported that the 5-year cumulative incidence of MGC even after successful H. pylori eradication was 15.0% during a 4.5-year median follow-up period [61]. This multicenter, prospective study also showed that 11% of MGCs (10 of 94) were detected more than 5 years after successful H. pylori eradication [61]. Therefore, continuous surveillance endoscopy should be performed to identify MGC in patients who have undergone ER for EGC, regardless of success or failure of H. pylori eradication.
EGC patients who undergo ER are at significant risk of developing MGC, but with annual or biannual surveillance EGD, MGC can be detected at an early stage when it is amenable to curative ESD resection. H. pylori eradication may reduce the incidence of MGC, but does not completely eradicate risk. Surveillance endoscopy should be continued indefinitely as cumulative incidence of MGC linearly increases. As we gain understanding of MGC, we hope that tailored surveillance intervals are developed, similar to those used to predict colonoscopy surveillance intervals based on the characteristics of the polyps removed. ESD for EGC preserves the quality of life by retaining the native stomach; however, the native stomach is at high risk for developing other gastric cancers. These patients should undergo life-long endoscopic surveillance for detection of MCG at an early and treatable stage.
Part of this work was supported by the National Cancer Center Research and Development Fund (25-A-12 and 28-K-1).
Table 1.
Incidence of Metachronous Gastric Cancer following Endoscopic Resection
Study Methods of endoscopic resection Rate of MGC Follow up period (yr) Annual incidence of MGC
Kim et al. (2007) [22] EMRa) 2.70% 11/379 1.9 Median -
Lee et al. (2011) [23] ESD 3.30%b) 15/458 2.2 Median -
Kato et al. (2013) [24] ESD 5.20% 65/1258 2.2 Mean 3.50%
Hahn et al. (2016) [25] ESD 4.30% 58/1347 2.4 Median 2.48%
Nakajima et al. (2006) [26] EMR and ESD 8.20% 52/633 4.4 Mean -
Nasu et al. (2005) [27] EMR 14% 20/143 4.8 Median Approximately 4%
Kobayashi et al. (2010) [28] EMR and ESD 12.80% 30/234 5 Median -
Min et al. (2015) [29] ESD 3.60% 47/1306 5 Median -
Abe et al. (2015) [30] ESD 15.60% 238/1527 6.6 Median -
Arima et al. (1999) [20] EMR 7.90% 6/76 7 -c) -

MGC, metachronous gastric cancer; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection.

a)Only R0 resection in patients with intramucosal cancer was included.

b)Synchronous lesion was included for analysis.

c)All patients were followed up for 7 year.

Table 2.
Intervals of Surveillance Endoscopy and Risk Factors of Metachronous Gastric Cancer following Endoscopic Resection
Study Intervals of Surveillance endoscopy for MGC Risk factors of metachronous gastric cancers
Lee et al. (2011) [23] Biannual then annual -
Kato et al. (2013) [24] Annual or biannual -
Hahn et al. (2016) [25] Annual or biannual Older age, intestinal metaplasia, ESD criteria
Nakajima et al. (2006) [26] Annual -
Nasu et al. (2005) [27] Annual -
Kobayashi et al. (2010) [28] Annual Multiple initial EGC, male, same third of the stomach
Min et al. (2015) [29] Annual or biannual Multiple initial EGC, well differentiated adenocarcinoma of initial EGC
Abe et al. (2015) [30] Annual or biannual Multiple initial EGC, male
Arima et al. (1999) [20] - Multiple initial EGC
Maehata et al. (2012) [35] Annual or biannual Follow-up period over 5 years, severe gastric mucosal atrophy
Kwon et al. (2014) [36] Annual Age ≥60 years old, persistent Helicobacter pylori infection
Kim et al. (2014) [37] Annual Age ≥65 years old, persistent H.pylori infection, family history of gastric cancer

MGC, metachronous gastric cancer; ESD, endoscopic submucosal dissection; EGC, early gastric cancer.

Table 3.
Incidence of Metachronous Gastric Cancer following Successful Helicobacter pylori Eradication
Study Design Numbera) Follow up Period (yr) Incidence Effect Results
Uemura et al. (1997) [51] NR 65/67 - - 0.0/9.0% Effective p=0.011
Fukase et al. (2008) [52] RCT 255/250 2.9/2.9a) Median 3.5/9.6% Effective p=0.003b), OR=0.34
Shiotani et al. (2008) [54] Single arm -/80 2.8 Median 11.3%
Maehata et al. (2012) [35] Retrospective 177/91 3 Median 8.5/14.3% Non-effective p=0.262
Choi et al. (2014) [53] RCT 439/441 3 Median 2.3/3.9% Non-effective p=0.15
Seo et al. (2013) [55] Retrospective 61/13 2.3 Mean 9.8/23.1% Non-effective p=0.189, OR=0.36
Chon et al. (2013) [56] Retrospective 85/44 2.2 Median 4.7/11.4% Effective p=0.008, HR=0.143
Kwon et al. (2014) [36] Retrospective 214/69 3.4 Median 4.7/14.5% Effective p=0.009
Kim et al. (2014) [37] Retrospective 49/107 5.3/4.6a) Median 4.1/15.0% Effective p=0.006
Bae et al. (2014) [57] Retrospective 485/182 5c) Median 7.0/13.2% Effective p=0.02, HR=1.9
14.7/29.7/1,000 pt yr
Jung et al. (2015) [58] Retrospective 506/169 3.3c) Median 4.2/5.9% Non-effective p=0.29, HR=0.67
Mori et al. (2016) [61] Single arm -/594 4.5 Median 29.9/1,000 pt yr

NR, non-randomized; RCT, randomized controlled trial; OR, odds ratio; HR, hazard ratio.

a)Eradicated group/Persistent infection group.

b)Modified intention to treat analysis.

c)Including gastric dysplasia, including Helicobacter pylori non-infection group.

  • 1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.ArticlePubMed
  • 2. Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 2013;16:1–27.ArticlePubMedPMC
  • 3. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219–225.ArticlePubMed
  • 4. Hirasawa T, Gotoda T, Miyata S, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 2009;12:148–152.ArticlePubMed
  • 5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113–123.ArticlePubMedPDF
  • 6. Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016;28:3–15.ArticlePubMed
  • 7. Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006;9:262–270.ArticlePubMed
  • 8. Isomoto H, Shikuwa S, Yamaguchi N, et al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut 2009;58:331–336.ArticlePubMed
  • 9. Goto O, Fujishiro M, Kodashima S, Ono S, Omata M. Outcomes of endoscopic submucosal dissection for early gastric cancer with special reference to validation for curability criteria. Endoscopy 2009;41:118–122.ArticlePubMed
  • 10. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010;97:868–871.ArticlePubMed
  • 11. Abe S, Oda I, Suzuki H, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy 2013;45:703–707.ArticlePubMedPDF
  • 12. Kosaka T, Endo M, Toya Y, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center retrospective study. Dig Endosc 2014;26:183–191.ArticlePubMed
  • 13. Tanabe S, Ishido K, Higuchi K, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. Gastric Cancer 2014;17:130–136.ArticlePubMed
  • 14. Oda I, Oyama T, Abe S, et al. Preliminary results of multicenter questionnaire study on long-term outcomes of curative endoscopic submucosal dissection for early gastric cancer. Dig Endosc 2014;26:214–219.ArticlePubMed
  • 15. Ohnita K, Isomoto H, Shikuwa S, et al. Early and long-term outcomes of endoscopic submucosal dissection for early gastric cancer in a large patient series. Exp Ther Med 2014;7:594–598.ArticlePubMedPMC
  • 16. Suzuki H, Oda I, Abe S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer 2016;19:198–205.ArticlePubMed
  • 17. Choi JH, Kim ES, Lee YJ, et al. Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer. Gastrointest Endosc 2015;82:299–307.ArticlePubMed
  • 18. Moertel CG, Bargen JA, Soule EH. Multiple gastric cancers; review of the literature and study of 42 cases. Gastroenterology 1957;32:1095–1103.ArticlePubMed
  • 19. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am 2000;29:819–827.ArticlePubMed
  • 20. Arima N, Adachi K, Katsube T, et al. Predictive factors for metachronous recurrence of early gastric cancer after endoscopic treatment. J Clin Gastroenterol 1999;29:44–47.ArticlePubMed
  • 21. Nishida T, Tsujii M, Kato M, et al. Endoscopic surveillance strategy after endoscopic resection for early gastric cancer. World J Gastrointest Pathophysiol 2014;5:100–106.ArticlePubMedPMC
  • 22. Kim JJ, Lee JH, Jung HY, et al. EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointest Endosc 2007;66:693–700.ArticlePubMed
  • 23. Lee H, Yun WK, Min BH, et al. A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc 2011;25:1985–1993.ArticlePubMed
  • 24. Kato M, Nishida T, Yamamoto K, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013;62:1425–1432.ArticlePubMed
  • 25. Hahn KY, Park JC, Kim EH, et al. Incidence and impact of scheduled endoscopic surveillance on recurrence after curative endoscopic resection for early gastric cancer. Gastrointest Endosc 2016;84:628–638.e1.ArticlePubMed
  • 26. Nakajima T, Oda I, Gotoda T, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006;9:93–98.ArticlePubMed
  • 27. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy 2005;37:990–993.ArticlePubMedPDF
  • 28. Kobayashi M, Narisawa R, Sato Y, Takeuchi M, Aoyagi Y. Self-limiting risk of metachronous gastric cancers after endoscopic resection. Dig Endosc 2010;22:169–173.ArticlePubMed
  • 29. Min BH, Kim ER, Kim KM, et al. Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. Endoscopy 2015;47:784–793.ArticlePubMedPDF
  • 30. Abe S, Oda I, Suzuki H, et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy 2015;47:1113–1118.ArticlePubMedPDF
  • 31. Onodera H, Tokunaga A, Yoshiyuki T, et al. Surgical outcome of 483 patients with early gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer. Hepatogastroenterology 2004;51:82–85.PubMed
  • 32. Hosokawa O, Kaizaki Y, Watanabe K, et al. Endoscopic surveillance for gastric remnant cancer after early cancer surgery. Endoscopy 2002;34:469–473.ArticlePubMedPDF
  • 33. Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg 2005;92:235–239.ArticlePubMed
  • 34. Nozaki I, Hato S, Kobatake T, et al. Incidence of metachronous gastric cancer in the remnant stomach after synchronous multiple cancer surgery. Gastric Cancer 2014;17:61–66.ArticlePubMed
  • 35. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39–46.ArticlePubMed
  • 36. Kwon YH, Heo J, Lee HS, Cho CM, Jeon SW. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment Pharmacol Ther 2014;39:609–618.ArticlePubMed
  • 37. Kim YI, Choi IJ, Kook MC, et al. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter 2014;19:194–201.ArticlePubMed
  • 38. Lim JH, Kim SG, Choi J, Im JP, Kim JS, Jung HC. Risk factors for synchronous or metachronous tumor development after endoscopic resection of gastric neoplasms. Gastric Cancer 2015;18:817–823.ArticlePubMed
  • 39. Venerito M, Malfertheiner P. Preneoplastic conditions in the stomach: always a point of no return? Dig Dis 2015;33:5–10.ArticlePubMed
  • 40. Zaky AH, Watari J, Tanabe H, et al. Clinicopathologic implications of genetic instability in intestinal-type gastric cancer and intestinal metaplasia as a precancerous lesion: proof of field cancerization in the stomach. Am J Clin Pathol 2008;129:613–621.ArticlePubMedPDF
  • 41. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 2008;134:500–510.ArticlePubMed
  • 42. Feng XY, Chen YB, Wang W, et al. Time-varying pattern of recurrence risk for gastric cancer patients. Med Oncol 2013;30:514.ArticlePubMed
  • 43. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121–128.ArticlePubMed
  • 44. Sipponen P, Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl 1993;196:3–6.ArticlePubMed
  • 45. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169–1179.ArticlePubMed
  • 46. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373–2379.ArticlePubMed
  • 47. Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur J Gastroenterol Hepatol 1994;6 Suppl 1:S79–S83.PubMed
  • 48. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1–241.PubMedPMC
  • 49. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.ArticlePubMed
  • 50. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005;100:1037–1042.ArticlePubMed
  • 51. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639–642.ArticlePubMed
  • 52. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392–397.ArticlePubMed
  • 53. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12:793–800.e1.ArticlePubMed
  • 54. Shiotani A, Uedo N, Iishi H, et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion 2008;78:113–119.ArticlePubMed
  • 55. Seo JY, Lee DH, Cho Y, et al. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology 2013;60:776–780.ArticlePubMed
  • 56. Chon I, Choi C, Shin CM, Park YS, Kim N, Lee DH. Effect of Helicobacter pylori eradication on subsequent dysplasia development after endoscopic resection of gastric dysplasia. Korean J Gastroenterol 2013;61:307–312.ArticlePubMed
  • 57. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014;109:60–67.ArticlePubMedPDF
  • 58. Jung DH, Kim JH, Lee YC, et al. Helicobacter pylori eradication reduces the metachronous recurrence of gastric neoplasms by attenuating the precancerous process. J Gastric Cancer 2015;15:246–255.ArticlePubMedPMC
  • 59. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014;19:243–248.ArticlePubMed
  • 60. Jung DH, Kim JH, Chung HS, et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One 2015;10:e0124725.ArticlePubMedPMC
  • 61. Mori G, Nakajima T, Asada K, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer 2016;19:911–918.ArticlePubMedPDF
  • 62. Ito M, Tanaka S, Takata S, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a shortterm follow-up. Aliment Pharmacol Ther 2005;21:559–566.ArticlePubMed
  • 63. Kobayashi M, Hashimoto S, Nishikura K, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol 2013;48:1332–1342.ArticlePubMed
  • 64. Yamamoto K, Kato M, Takahashi M, et al. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter 2011;16:210–216.ArticlePubMed
  • 65. Moribata K, Iguchi JK, Nakachi K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc 2015 Dec 1 [Epub]. https://doi.org/10.1111/den.12581ArticlePMC
  • 66. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer version I. 2016 [Internet]. Fort Washington (PA): National Comprehensive Cancer Network; c2016 [cited 2016 Mar 31]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf
  • 67. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844–857.ArticlePubMed
  • 68. Asada K, Nakajima T, Shimazu T, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 2015;64:388–396.ArticlePubMedPMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review
      Shailja C. Shah, Andrew Y. Wang, Michael B. Wallace, Joo Ha Hwang
      Gastroenterology.2025; 168(2): 405.     CrossRef
    • Gastric remnant cancer: a comprehensive narrative review from carcinogenesis to treatment
      José Darío Portillo-Miño, Sandra Cifuentes, Javier Morales, Melissa Bastidas, William Otero, Paulo Pimentel de Assumpção, Gonzalo Latorre, Megan Neumann, Arnoldo Riquelme
      Revista de Gastroenterología del Perú.2025; 45(3): 282.     CrossRef
    • Impact of endoscopy intervals on metachronous gastric cancer after endoscopic submucosal dissection: Comparison between 1 year and half‐a‐year
      Yuichiro Ozeki, Kingo Hirasawa, Atsushi Sawada, Ryosuke Ikeda, Masafumi Nishio, Takehide Fukuchi, Ryosuke Kobayashi, Chiko Sato, Shin Maeda
      Digestive Endoscopy.2024; 36(3): 332.     CrossRef
    • High risk of multiple gastric cancers in Japanese individuals with Lynch syndrome
      Nobuhiko Kanaya, Thijs A. van Schaik, Hideki Aoki, Yumiko Sato, Fumitaka Taniguchi, Kunitoshi Shigeyasu, Kokichi Sugano, Kiwamu Akagi, Hideyuki Ishida, Kohji Tanakaya
      Annals of Gastroenterological Surgery.2024; 8(6): 1008.     CrossRef
    • Clinical outcomes of ablation of gastric dysplasia with argon plasma coagulation
      Mi Jin Oh, Sang Gyun Kim, Jiyoon Kim, Yun Suk Na, Seunghan Lee, Junhee Lee, Bokyung Kim, Hyunsoo Chung, Soo-Jeong Cho, Miquel Vall-llosera Camps
      PLOS ONE.2024; 19(7): e0306934.     CrossRef
    • Optimal Surveillance of Metachronous Gastric Lesion after Endoscopic Resection of Early Gastric Cancer
      Dong Chan Joo, Gwang Ha Kim
      Gut and Liver.2024; 18(5): 781.     CrossRef
    • Latest guideline of endoscopic submucosal dissection of early gastric cancer may not be suitable for Chinese patients: retrospective study findings from two centers
      Yu Mei, Jianpeng Gao, Benyan Zhang, Tienan Feng, Wei Wu, Zhenggang Zhu, Zhenglun Zhu
      Surgical Endoscopy.2024; 38(11): 6726.     CrossRef
    • Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study
      Yun Suk Na, Sang Gyun Kim, Soo-Jeong Cho
      Gastric Cancer.2023; 26(2): 298.     CrossRef
    • Metachronous lesions after gastric endoscopic submucosal dissection: first assessment of the FAMISH prediction score
      Andreia Rei, Raquel Ortigão, Mariana Pais, Luís P. Afonso, Pedro Pimentel-Nunes, Mário Dinis-Ribeiro, Diogo Libânio
      Endoscopy.2023; 55(10): 909.     CrossRef
    • Variation in the rate of detection of minute and small early gastric cancers at diagnostic endoscopy may reflect the performance of individual endoscopists
      Daisuke Murakami, Masayuki Yamato, Yuji Amano, Takayoshi Nishino, Makoto Arai
      BMJ Open Gastroenterology.2023; 10(1): e001143.     CrossRef
    • Decision to perform additional surgery after non-curative endoscopic submucosal dissection for gastric cancer based on the risk of lymph node metastasis: a long-term follow-up study
      Seunghan Lee, Sang Gyun Kim, Soo-Jeong Cho
      Surgical Endoscopy.2023; 37(10): 7738.     CrossRef
    • Helicobacter pylori Eradication Can Reverse Rho GTPase Expression in Gastric Carcinogenesis
      Jue Lie Kim, Sang Gyun Kim, Enerelt Natsagdorj, Hyunsoo Chung, Soo-Jeong Cho
      Gut and Liver.2023; 17(5): 741.     CrossRef
    • Risk assessment of metachronous gastric cancer after endoscopic submucosal dissection based on endoscopic intestinal metaplasia
      Chino Iizuka, Soichiro Sue, Sho Onodera, Aya Ikeda, Ryosuke Ikeda, Yoshihiro Goda, Kuniyasu Irie, Hiroaki Kaneko, Shin Maeda
      JGH Open.2023; 7(11): 783.     CrossRef
    • Second gastric cancer after curative endoscopic resection of differentiated-type early gastric cancer: post-hoc analysis of a single-arm confirmatory trial
      Masao Yoshida, Kohei Takizawa, Noriaki Hasuike, Hiroyuki Ono, Narikazu Boku, Tomohiro Kadota, Junki Mizusawa, Ichiro Oda, Naohiro Yoshida, Yusuke Horiuchi, Kingo Hirasawa, Yoshinori Morita, Yoshinobu Yamamoto, Manabu Muto, Masao Yoshida, Kohei Takizawa, H
      Gastrointestinal Endoscopy.2022; 95(4): 650.     CrossRef
    • Therapeutic approach to non-curative resection after endoscopic treatment in early gastric cancer
      Eun Jeong Gong, Chang Seok Bang
      Journal of the Korean Medical Association.2022; 65(5): 284.     CrossRef
    • Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan
      Yoshinobu Yamamoto, Naohiro Yoshida, Tomonori Yano, Takahiro Horimatsu, Noriya Uedo, Noboru Kawata, Hiromitsu Kanzaki, Shinichiro Hori, Kenshi Yao, Seiichiro Abe, Chikatoshi Katada, Chizu Yokoi, Ken Ohata, Hisashi Doyama, Kenichi Yoshimura, Hideki Ishikaw
      JAMA Network Open.2022; 5(8): e2227667.     CrossRef
    • Management of patients with multiple primary сancer in the practice of a modern oncologist. Case report and literature review
      D. A. Khlanta, G. P. Gens
      Siberian journal of oncology.2022; 21(4): 147.     CrossRef
    • Assigning a different endoscopist for each annual follow-up may contribute to improved gastric cancer detection rates
      Shuhei Unno, Kimihiro Igarashi, Hiroaki Saito, Dai Hirasawa, Toru Okuzono, Yukari Tanaka, Masato Nakahori, Tomoki Matsuda
      Endoscopy International Open.2022; 10(10): E1333.     CrossRef
    • Statistical proof of Helicobacter pylori eradication in preventing metachronous gastric cancer after endoscopic resection in an East Asian population
      Mohsen Karbalaei, Masoud Keikha
      World Journal of Gastrointestinal Surgery.2022; 14(8): 867.     CrossRef
    • Follow-up after endoscopic resection for early gastric cancer in 3 French referral centers
      Bernadette de Rauglaudre, Mathieu Pioche, Fabrice Caillol, Jean-Philippe Ratone, Anna Pellat, Romain Coriat, Jerôme Rivory, Thomas Lambin, Laetitia Dahan, Marc Giovanini, Maximilien Barret
      iGIE.2022; 1(1): 49.     CrossRef
    • Documento de posicionamiento de la AEG, la SEED y la SEAP sobre cribado de cáncer gástrico en poblaciones con baja incidencia
      Joaquín Cubiella, Ángeles Pérez Aisa, Miriam Cuatrecasas, Pilar Díez Redondo, Gloria Fernández Esparrach, José Carlos Marín-Gabriel, Leticia Moreira, Henar Núñez, M. Luisa Pardo López, Enrique Rodríguez de Santiago, Pedro Rosón, José Miguel Sanz Anquela,
      Gastroenterología y Hepatología.2021; 44(1): 67.     CrossRef
    • Incidence of metachronous cancer after endoscopic submucosal dissection: a comparison between undifferentiated-type and differentiated-type early gastric cancer
      Mitsuaki Ishioka, Toshiyuki Yoshio, Yuji Miyamoto, Ken Namikawa, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiaki Hirasawa, Tomohiro Tsuchida, Junko Fujisaki
      Gastrointestinal Endoscopy.2021; 93(3): 557.     CrossRef
    • Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP
      Joaquin Cubiella, Ángeles Pérez Aisa, Miriam Cuatrecasas, Pilar Díez Redondo, Gloria Fernández Esparrach, José Carlos Marín-Gabriel, Leticia Moreira, Henar Núñez, M. Luisa Pardo López, Enrique Rodríguez de Santiago, Pedro Rosón, José Miguel Sanz Anquela,
      Gastroenterología y Hepatología (English Edition).2021; 44(1): 67.     CrossRef
    • Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study
      Ho Suk Kang, Mi Jung Kwon, Premi Haynes, Yan Liang, Yuqi Ren, Hyun Lim, Jae Seung Soh, Nan Young Kim, Hye Kyung Lee
      Pathology - Research and Practice.2021; 222: 153434.     CrossRef
    • Characteristics of metachronous gastric neoplasms after curative endoscopic submucosal dissection for early gastric neoplasms
      Shan-Shan Xu, Ning-Li Chai, Xiao-Wei Tang, En-Qiang Linghu, Sha-Sha Wang, Bao Li
      Chinese Medical Journal.2021; 134(21): 2603.     CrossRef
    • Consenso mexicano sobre detección y tratamiento del cáncer gástrico incipiente
      M.E. Icaza-Chávez, M.A. Tanimoto, F.M. Huerta-Iga, J.M. Remes-Troche, R. Carmona-Sánchez, A. Ángeles-Ángeles, F.J. Bosques-Padilla, J.M. Blancas-Valencia, G. Grajales-Figueroa, O.V. Hernández-Mondragón, A.I. Hernández-Guerrero, M.A. Herrera-Servín, F.D. H
      Revista de Gastroenterología de México.2020; 85(1): 69.     CrossRef
    • The Mexican consensus on the detection and treatment of early gastric cancer
      M.E. Icaza-Chávez, M.A. Tanimoto, F.M. Huerta-Iga, J.M. Remes-Troche, R. Carmona-Sánchez, A. Ángeles-Ángeles, F.J. Bosques-Padilla, J.M. Blancas-Valencia, G. Grajales-Figueroa, O.V. Hernández-Mondragón, A.I. Hernández-Guerrero, M.Á. Herrera-Servín, F.D. H
      Revista de Gastroenterología de México (English Edition).2020; 85(1): 69.     CrossRef
    • Long‐term follow up of serum pepsinogens in patients with gastric cancer or dysplasia after Helicobacter pylori eradication
      Gitark Noh, Nayoung Kim, Yonghoon Choi, Hye Seung Lee, Young Jae Hwang, Hee Jin Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee
      Journal of Gastroenterology and Hepatology.2020; 35(9): 1540.     CrossRef
    • Metachronous Gastric Cancer: Another Hurdle for Successful Endoscopic Treatment for Early Gastric Cancer?
      Moon Won Lee, Gwang Ha Kim
      Gut and Liver.2020; 14(2): 145.     CrossRef
    • Clinical Outcomes of Metachronous Gastric Cancer after Endoscopic Resection for Early Gastric Cancer
      Jue Lie Kim, Sang Gyun Kim, Jung Kim, Jae Yong Park, Hyo-Joon Yang, Hyun Ju Kim, Hyunsoo Chung
      Gut and Liver.2020; 14(2): 190.     CrossRef
    • Chemoprevention of gastric cancer development afterHelicobacter pylorieradication therapy in an East Asian population: Meta-analysis
      Mitsushige Sugimoto, Masaki Murata, Yoshio Yamaoka
      World Journal of Gastroenterology.2020; 26(15): 1820.     CrossRef
    • MULTIFOCAL EARLY GASTRIC CANCER IN A PATIENT WITH ATROPHIC GASTRITIS AND PERNICIOUS ANEMIA
      Tommaso Zurleni, Michele Altomare, Giovanni Serio, Filippo Catalano
      International Journal of Surgery Case Reports.2020;[Epub]     CrossRef
    • Impact of the timing of Helicobacter pylori eradication on the risk of development of metachronous lesions after treatment of early gastric cancer: a population-based cohort study
      Hyun Ju Kim, Yun Jin Kim, Seung In Seo, Woon Geon Shin, Chan Hyuk Park
      Gastrointestinal Endoscopy.2020; 92(3): 613.     CrossRef
    • Gastric cancer prevention strategies: A global perspective
      Leonardo Henry Eusebi, Andrea Telese, Giovanni Marasco, Franco Bazzoli, Rocco Maurizio Zagari
      Journal of Gastroenterology and Hepatology.2020; 35(9): 1495.     CrossRef
    • Metachronous Gastric Cancer Occurring after Endoscopic Resection of Early Gastric Cancer
      Gwang Ha Kim
      The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2020; 20(4): 295.     CrossRef
    • Somatic alterations and mutational burden are potential predictive factors for metachronous development of early gastric cancer
      Kazuhiro Sakuta, Yu Sasaki, Yasuhiko Abe, Hidenori Sato, Masakuni Shoji, Takao Yaoita, Makoto Yagi, Naoko Mizumoto, Yusuke Onozato, Takashi Kon, Ayumi Koseki, Sonoko Sato, Ryoko Murakami, Yuki Miyano, Yoshiyuki Ueno
      Scientific Reports.2020;[Epub]     CrossRef
    • Clinicopathologic Characteristics of Patients with Gastric Superficial Neoplasia and Risk Factors for Multiple Lesions after Endoscopic Submucosal Dissection in a Western Country
      Gisela Brito-Gonçalves, Diogo Libânio, Pedro Marcos, Inês Pita, Rui Castro, Inês Sá, Mário Dinis-Ribeiro, Pedro Pimentel-Nunes
      GE - Portuguese Journal of Gastroenterology.2020; 27(2): 76.     CrossRef
    • Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis
      Shiyu Xiao, Sizhu Li, Liya Zhou, Wenjun Jiang, Jinzhe Liu
      Journal of Gastroenterology.2019; 54(3): 226.     CrossRef
    • Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
      Alexios-Fotios A. Mentis, Efthimios Dardiotis
      Frontiers in Oncology.2019;[Epub]     CrossRef
    • Common Locations of Gastric Cancer: Review of Research from the Endoscopic Submucosal Dissection Era
      Su Jin Kim, Cheol Woong Choi
      Journal of Korean Medical Science.2019;[Epub]     CrossRef
    • UEG Week 2019 Poster Presentations

      United European Gastroenterology Journal.2019; 7(S8): 189.     CrossRef
    • Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer
      Lan Li, Chaohui Yu
      BioMed Research International.2019; 2019: 1.     CrossRef
    • Prophylaxis and early diagnosis of stomach cancer
      I. G. Bakulin, S. S. Pirogov, N. V. Bakulina, E. A. Stadnik, N. N. Golubev
      Dokazatel'naya gastroenterologiya.2018; 7(2): 44.     CrossRef
    • Linked Color Imaging and Blue Laser Imaging for Upper Gastrointestinal Screening
      Hiroyuki Osawa, Yoshimasa Miura, Takahito Takezawa, Yuji Ino, Tsevelnorov Khurelbaatar, Yuichi Sagara, Alan Kawarai Lefor, Hironori Yamamoto
      Clinical Endoscopy.2018; 51(6): 513.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer
      Clin Endosc. 2018;51(3):253-259.   Published online September 18, 2017
      DOI: https://doi.org/10.5946/ce.2017.104
      Close
    • XML DownloadXML Download
    Related articles
    Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer
    Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer
    Study Methods of endoscopic resection Rate of MGC Follow up period (yr) Annual incidence of MGC
    Kim et al. (2007) [22] EMRa) 2.70% 11/379 1.9 Median -
    Lee et al. (2011) [23] ESD 3.30%b) 15/458 2.2 Median -
    Kato et al. (2013) [24] ESD 5.20% 65/1258 2.2 Mean 3.50%
    Hahn et al. (2016) [25] ESD 4.30% 58/1347 2.4 Median 2.48%
    Nakajima et al. (2006) [26] EMR and ESD 8.20% 52/633 4.4 Mean -
    Nasu et al. (2005) [27] EMR 14% 20/143 4.8 Median Approximately 4%
    Kobayashi et al. (2010) [28] EMR and ESD 12.80% 30/234 5 Median -
    Min et al. (2015) [29] ESD 3.60% 47/1306 5 Median -
    Abe et al. (2015) [30] ESD 15.60% 238/1527 6.6 Median -
    Arima et al. (1999) [20] EMR 7.90% 6/76 7 -c) -
    Study Intervals of Surveillance endoscopy for MGC Risk factors of metachronous gastric cancers
    Lee et al. (2011) [23] Biannual then annual -
    Kato et al. (2013) [24] Annual or biannual -
    Hahn et al. (2016) [25] Annual or biannual Older age, intestinal metaplasia, ESD criteria
    Nakajima et al. (2006) [26] Annual -
    Nasu et al. (2005) [27] Annual -
    Kobayashi et al. (2010) [28] Annual Multiple initial EGC, male, same third of the stomach
    Min et al. (2015) [29] Annual or biannual Multiple initial EGC, well differentiated adenocarcinoma of initial EGC
    Abe et al. (2015) [30] Annual or biannual Multiple initial EGC, male
    Arima et al. (1999) [20] - Multiple initial EGC
    Maehata et al. (2012) [35] Annual or biannual Follow-up period over 5 years, severe gastric mucosal atrophy
    Kwon et al. (2014) [36] Annual Age ≥60 years old, persistent Helicobacter pylori infection
    Kim et al. (2014) [37] Annual Age ≥65 years old, persistent H.pylori infection, family history of gastric cancer
    Study Design Numbera) Follow up Period (yr) Incidence Effect Results
    Uemura et al. (1997) [51] NR 65/67 - - 0.0/9.0% Effective p=0.011
    Fukase et al. (2008) [52] RCT 255/250 2.9/2.9a) Median 3.5/9.6% Effective p=0.003b), OR=0.34
    Shiotani et al. (2008) [54] Single arm -/80 2.8 Median 11.3%
    Maehata et al. (2012) [35] Retrospective 177/91 3 Median 8.5/14.3% Non-effective p=0.262
    Choi et al. (2014) [53] RCT 439/441 3 Median 2.3/3.9% Non-effective p=0.15
    Seo et al. (2013) [55] Retrospective 61/13 2.3 Mean 9.8/23.1% Non-effective p=0.189, OR=0.36
    Chon et al. (2013) [56] Retrospective 85/44 2.2 Median 4.7/11.4% Effective p=0.008, HR=0.143
    Kwon et al. (2014) [36] Retrospective 214/69 3.4 Median 4.7/14.5% Effective p=0.009
    Kim et al. (2014) [37] Retrospective 49/107 5.3/4.6a) Median 4.1/15.0% Effective p=0.006
    Bae et al. (2014) [57] Retrospective 485/182 5c) Median 7.0/13.2% Effective p=0.02, HR=1.9
    14.7/29.7/1,000 pt yr
    Jung et al. (2015) [58] Retrospective 506/169 3.3c) Median 4.2/5.9% Non-effective p=0.29, HR=0.67
    Mori et al. (2016) [61] Single arm -/594 4.5 Median 29.9/1,000 pt yr
    Table 1. Incidence of Metachronous Gastric Cancer following Endoscopic Resection

    MGC, metachronous gastric cancer; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection.

    Only R0 resection in patients with intramucosal cancer was included.

    Synchronous lesion was included for analysis.

    All patients were followed up for 7 year.

    Table 2. Intervals of Surveillance Endoscopy and Risk Factors of Metachronous Gastric Cancer following Endoscopic Resection

    MGC, metachronous gastric cancer; ESD, endoscopic submucosal dissection; EGC, early gastric cancer.

    Table 3. Incidence of Metachronous Gastric Cancer following Successful Helicobacter pylori Eradication

    NR, non-randomized; RCT, randomized controlled trial; OR, odds ratio; HR, hazard ratio.

    Eradicated group/Persistent infection group.

    Modified intention to treat analysis.

    Including gastric dysplasia, including Helicobacter pylori non-infection group.

    Table 1.

    Table 2.

    Table 3.

    Clin Endosc : Clinical Endoscopy Twitter Facebook
    © Korean Society of Gastrointestinal Endoscopy.
    Close layer
    TOP